Form 8-K - Current report:
SEC Accession No. 0001104659-25-019467
Filing Date
2025-03-03
Accepted
2025-03-03 07:12:51
Documents
17
Period of Report
2025-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm258007d1_8k.htm   iXBRL 8-K 27885
2 EXHIBIT 99.1 tm258007d1_ex99-1.htm EX-99.1 68178
3 EXHIBIT 99.2 tm258007d1_ex99-2.htm EX-99.2 23755
7 GRAPHIC tm258007d1_ex99-1img002.jpg GRAPHIC 3072
8 GRAPHIC tm258007d1_ex99-2img001.jpg GRAPHIC 3072
  Complete submission text file 0001104659-25-019467.txt   323553

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apge-20250303.xsd EX-101.SCH 3045
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apge-20250303_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apge-20250303_pre.xml EX-101.PRE 22379
19 EXTRACTED XBRL INSTANCE DOCUMENT tm258007d1_8k_htm.xml XML 3815
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 25693758
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)